Universal Therapeutics Diagnostics Awarded Exclusive Supply Contract with Ministry of Health Malaysia for Syphilis Rapid Test Cassettes
FOR IMMEDIATE RELEASE
26 February 2025
Kuala Lumpur, Malaysia
New Agreement Ensures Improved National Syphilis Testing Capacity from 2025 to 2027
Universal Therapeutics Diagnostics, a subsidiary of Universal Therapeutics Group Sdn Bhd is proud to announce that it has been awarded an exclusive supply contract by the Ministry of Health Malaysia (MOH) for its UT + DIAGNOSTICS Syphilis Rapid Test Cassette. Commencing in 2025 and spanning two years, this agreement involves the provision of two million test cassettes to MOH facilities and partner organisations throughout Malaysia.
The UT + DIAGNOSTICS Syphilis Rapid Test Cassette is a highly accurate, user-friendly diagnostic device designed to detect syphilis antibodies in human serum, plasma, or whole blood. By delivering rapid results, it supports early detection and treatment of syphilis, thereby aligning with national public health strategies aimed at controlling and eliminating sexually transmitted infections.
Key Points of the Agreement
· Exclusive Supplier: Universal Therapeutics Diagnostics will serve as the sole supplier of the UT + DIAGNOSTICS Syphilis Rapid Test Cassette to the Ministry of Health Malaysia.
· Contract Duration: The agreement covers the period from 2025 to 2027 (two years in total).
· Volume: Two million test cassettes will be delivered over the contract term, ensuring robust support for nationwide healthcare requirements.
· Impact: This initiative underpins the Ministry’s efforts to enhance syphilis screening, reduce transmission rates, and improve overall public health outcomes.
“This exclusive supply contract reaffirms our dedication to supporting Malaysia’s healthcare system with cutting-edge diagnostic solutions,” said Dato’ Sri Samuel Chai, Chief Executive Officer of Universal Therapeutics Diagnostics. “Our UT + DIAGNOSTICS Syphilis Rapid Test Cassette provides rapid, accurate results, enabling healthcare professionals to make timely decisions and ultimately improve patient outcomes.”
Recent public health data underscores the importance of early diagnosis in managing and mitigating the spread of infections such as syphilis. By equipping hospitals, clinics, and laboratories with advanced rapid diagnostic tests, Universal Therapeutics Diagnostics aims to bolster Malaysia’s capacity to prevent and control sexually transmitted infections.
“This contract represents a significant milestone for Universal Therapeutics Diagnostics and demonstrates the Ministry of Health Malaysia’s confidence in our product range,” added Dr. Erica Koh, Head of Product Development at Universal Therapeutics Diagnostics. “We remain committed to innovating, developing, and delivering high-quality diagnostic tools that address the evolving needs of healthcare providers and their patients.”
Universal Therapeutics Diagnostics remains steadfast in its commitment to maintaining excellence in medical product development and fostering effective collaborations with global health authorities, while upholding the highest standards of quality and reliability.
For further information about Universal Therapeutics Diagnostics, our products, or this exclusive contract, please visit www.Universal-Therapeutics.com or contact Josephine Kim at PR1@Universal-Therapeutics.com.
About Universal Therapeutics Diagnostics
Universal Therapeutics Diagnostics is a subsidiary of Universal Therapeutics Group specialising in innovative healthcare solutions and medical diagnostics. Through continuous research and development, Universal Therapeutics Diagnostics provides healthcare authorities and professionals with accessible, cost-effective, and high-performance diagnostic tools to enhance patient care worldwide.
Media Enquiries:
Josephine KIM (Miss)
Communications Manager
PR1@Universal-Therapeutics.com